NeoGenomics, Inc.: NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE DNA and RNA Assay

FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today

Related Keywords

Fort Myers ,Florida ,United States ,Georgia ,Tampa ,North Carolina ,United Kingdom ,Texas ,Research Triangle Park ,Atlanta ,California ,San Diego ,Arizona ,Tennessee ,Singapore ,Phoenix ,Houston ,Aliso Viejo ,Cambridge ,Cambridgeshire ,Switzerland ,Derek Lyle ,Eli Lilly ,Anthony Nino Sireci ,Clinical Division Of Neogenomics ,Neogenomics Inc ,Lilly Lung Cancer Sponsored Testing Program ,Company Pharma Services Division ,Nasdaq ,Company Annual Report On Form ,Diagnostics Development ,Lungliquid Biopsy ,Chief Medical Officer ,Clinical Division ,Generation Sequencing ,Vice President ,Clinical Biomarkers ,Loxo Oncology ,Pharma Services Division ,Privacy Practices ,Private Securities Litigation Reform Act ,Annual Report ,Neogenomics ,Nnounces ,Partnership ,Illy ,Young ,Dancer ,Sponsored ,Testing ,Program ,Tilizing ,Eotype ,Essay ,